NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Achieving Superior Responses in Breast Cancer Immunotherapy Trials
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment,” featuring BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT).
To hear the NetworkNewsAudio version, visit: http://nnw.fm/0UHqY
To read the full editorial, visit: http://nnw.fm/Ixnq5
As earlier noted, BriaCell achieved proof-of-concept in its phase IIa study of Bria-IMT with positive safety and excellent, predictable efficacy in patients with HLA matches with Bria-IMT. Importantly, initial safety data appeared superior to that of the other advanced or approved drugs for breast cancer when they were at a similar clinical stage of development. Most importantly, initial efficacy data was similar or superior to those of other advanced or approved drugs for breast cancer when they were at a similar clinical stage of development.
Based on BriaCell’s observation of superior tumor shrinking responses in the patients who shared certain biomarkers (i.e., HLA types) with Bria-IMT, BriaCell is developing Bria-OTS for advanced breast cancer. Bria-OTS includes a set of cell lines, each being similar to Bria-IMT, which are being engineered to express various premanufactured HLA types. With only 15 different HLA types, Bria-OTS cell line combinations are expected to cover more than 90 percent of the United States’ population. Bria-OTS is expected to enter the clinics in 2019.
BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body’s own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to prevent cancer recurrence. For more information, visit the company’s website at www.briacell.com.
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact: